SCHEMBL5137932

SCHEMBL5137932

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(CO)cc1)Cc1cccc(OC)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.44
CALM1 P0DP23 1/20 0.40
CAMKK2 Q96RR4 1/20 0.40
CNR2 P34972 1/20 0.40
TLR7 Q9NYK1 1/20 0.39
HSP90AA1 P07900 1/20 0.38
HSP90AB1 P08238 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CSF1R P07333 1/20 0.38
NR1H2 P55055 1/20 0.37
NR1H3 Q13133 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
MAPT P10636 2/20 0.37
PPARG P37231 1/20 0.37
TSHR P16473 5/20 0.37
HSD17B10 Q99714 1/20 0.37
MAPK1 P28482 1/20 0.36
ALDH1A1 P00352 1/20 0.36
BCL2L1 Q07817 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135433 0.95 C5AR1 (0.46) C5AR1CALM1CAMKK2CNR2TLR7
SCHEMBL648419 0.94 C5AR1 (0.46) C5AR1CALM1CAMKK2CNR2TLR7
SCHEMBL5147943 0.92 C5AR1 (0.43) C5AR1CNR2HSP90AA1HSP90AB1SMN1; SMN2
SCHEMBL5136578 0.92 C5AR1 (0.43) C5AR1CNR2SMN1; SMN2MAPTTSHR
SCHEMBL5135383 0.90 C5AR1 (0.45) C5AR1CALM1CAMKK2CNR2TLR7
SCHEMBL5136482 0.90 C5AR1 (0.47) C5AR1SMN1; SMN2NR1H3TSHRHSD17B10
SCHEMBL5136530 0.89 C5AR1 (0.41) C5AR1CNR2TLR7MEN1KMT2A
SCHEMBL5135705 0.89 CALM1 (0.45) C5AR1CALM1CAMKK2CNR2TLR7
SCHEMBL5137491 0.89 CALM1 (0.45) C5AR1CALM1CAMKK2CNR2TLR7
SCHEMBL652044 0.89 C5AR1 (0.43) C5AR1CALM1CAMKK2TLR7HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed